well momelotinib's label is not restricted to second line, and NVS is going to be motivated to test pelabresib w momelotinib to compete w INCY assuming their BET inhibitor moves into combo w jakafi, so I do think the data will be generated in due course
If all these combos cross the finish line choice may end up based on toxicity bc efficacy may not be much different. momelotinib may be better for more anemic patients, jakafi may ahve less neuropathy, etc
Market Data 
Markets 
AI
